Potential prognostic value of PD-L1 and NKG2A expression in Indonesian patients with skin nodular melanoma

[1]  D. Schadendorf,et al.  Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Friederike Hoffmann,et al.  Prognostic and predictive value of PD-L2 DNA methylation and mRNA expression in melanoma , 2020, Clinical Epigenetics.

[3]  S. H. van der Burg,et al.  The NKG2A–HLA-E Axis as a Novel Checkpoint in the Tumor Microenvironment , 2020, Clinical Cancer Research.

[4]  Zheyan Liu,et al.  A pooled analysis of the prognostic value of PD-L1 in melanoma: evidence from 1062 patients , 2020, Cancer Cell International.

[5]  S. H. van der Burg,et al.  Monalizumab: inhibiting the novel immune checkpoint NKG2A , 2019, Journal of Immunotherapy for Cancer.

[6]  D. Rimm,et al.  Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma , 2019, Journal of Immunotherapy for Cancer.

[7]  G. Hortobagyi,et al.  Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy. , 2019, Cancer cell.

[8]  Clara Di Vito,et al.  Targeting NKG2A to elucidate natural killer cell ontogenesis and to develop novel immune‐therapeutic strategies in cancer therapy , 2019, Journal of leukocyte biology.

[9]  N. Safwat,et al.  Natural killer NKG2A and NKG2D in patients with colorectal cancer. , 2019, Journal of gastrointestinal oncology.

[10]  J. Madore,et al.  Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients , 2018, Oncoimmunology.

[11]  P. Soares,et al.  Melanoma treatment in review , 2018, ImmunoTargets and therapy.

[12]  Chao Xie,et al.  Overexpression of mRNA-decapping enzyme 1a predicts disease-specific survival in malignant melanoma , 2018, Melanoma research.

[13]  A. Russo,et al.  Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone? , 2018, Cellular immunology.

[14]  Zhongwu Li,et al.  The Prognostic Value of HRAS mRNA Expression in Cutaneous Melanoma , 2017, BioMed research international.

[15]  F. Orso,et al.  PD-L1 up-regulation in melanoma increases disease aggressiveness and is mediated through miR-17-5p , 2017, Oncotarget.

[16]  C. Slingluff,et al.  PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcome , 2016, Oncoimmunology.

[17]  O. Abdel-Rahman.  PD-L1 expression and outcome of advanced melanoma patients treated with anti-PD-1/PD-L1 agents: a meta-analysis. , 2016, Immunotherapy.

[18]  A. Scorilas,et al.  Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma , 2015, Clinical Cancer Research.

[19]  M. Mandalà,et al.  The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  Razelle Kurzrock,et al.  PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy , 2015, Molecular Cancer Therapeutics.

[21]  Samuel Müller,et al.  Determination of prognosis in metastatic melanoma through integration of clinico‐pathologic, mutation, mRNA, microRNA, and protein information , 2015, International journal of cancer.

[22]  A. Carrato,et al.  The status of PD-L1 and tumor-in fi ltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAF V600 , 2015 .

[23]  Alison P. Klein,et al.  Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape , 2012, Science Translational Medicine.